JP2014221834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014221834A5 JP2014221834A5 JP2014167336A JP2014167336A JP2014221834A5 JP 2014221834 A5 JP2014221834 A5 JP 2014221834A5 JP 2014167336 A JP2014167336 A JP 2014167336A JP 2014167336 A JP2014167336 A JP 2014167336A JP 2014221834 A5 JP2014221834 A5 JP 2014221834A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- tumor
- level
- subject
- precursor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091060585 Mir-31 Proteins 0.000 claims 35
- 238000000034 method Methods 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 21
- 239000002243 precursor Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 238000012360 testing method Methods 0.000 claims 10
- 239000012472 biological sample Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 206010027476 Metastases Diseases 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- 230000009401 metastasis Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108091032087 miR-31a stem-loop Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12032208P | 2008-12-05 | 2008-12-05 | |
| US61/120,322 | 2008-12-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539777A Division JP2012511031A (ja) | 2008-12-05 | 2009-12-07 | ｍｉＲ−３１に関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014221834A JP2014221834A (ja) | 2014-11-27 |
| JP2014221834A5 true JP2014221834A5 (cg-RX-API-DMAC7.html) | 2015-02-19 |
| JP6110346B2 JP6110346B2 (ja) | 2017-04-05 |
Family
ID=42233912
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539777A Pending JP2012511031A (ja) | 2008-12-05 | 2009-12-07 | ｍｉＲ−３１に関連する組成物および方法 |
| JP2014167336A Expired - Fee Related JP6110346B2 (ja) | 2008-12-05 | 2014-08-20 | ｍｉＲ−３１に関連する組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539777A Pending JP2012511031A (ja) | 2008-12-05 | 2009-12-07 | ｍｉＲ−３１に関連する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120041048A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2370091B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2012511031A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009322137B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2745919A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010065961A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003346A2 (en) * | 2011-06-27 | 2013-01-03 | Medimmune, Llc | Microrna-31 compositions and methods for use in autoimmune disease |
| CN102776191A (zh) * | 2012-07-20 | 2012-11-14 | 苏州大学 | 一种微小rna用于调控cd86的基因表达 |
| JP6519927B2 (ja) * | 2013-09-06 | 2019-05-29 | 国立大学法人 東京大学 | 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用 |
| WO2015164786A1 (en) * | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| ES2877689T3 (es) * | 2014-05-02 | 2021-11-17 | Univ Heidelberg Ruprecht Karls | miARN circulantes como marcador de detección temprana y marcador pronóstico |
| US9623040B2 (en) * | 2014-07-14 | 2017-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Immunomodulation by controlling expression levels of microRNAs in dendritic cells |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| WO2016131009A1 (en) | 2015-02-13 | 2016-08-18 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| WO2018183594A1 (en) * | 2017-03-29 | 2018-10-04 | Children's Hospital Medical Center | Nucleic acid molecules and their methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1726199A (en) * | 1997-12-31 | 1999-07-19 | Chiron Corporation | Metastatic cancer regulated gene |
| EP1953229A3 (en) * | 1998-10-15 | 2008-12-24 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
| KR20050115231A (ko) * | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| US20080014579A1 (en) * | 2003-02-11 | 2008-01-17 | Affymetrix, Inc. | Gene expression profiling in colon cancers |
| US20050193432A1 (en) | 2003-11-18 | 2005-09-01 | Whitehead Institute For Biomedical Research | Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof |
| WO2005113770A1 (en) * | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
| AU2005333165B2 (en) | 2004-11-12 | 2012-07-19 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| WO2006061430A2 (en) * | 2004-12-10 | 2006-06-15 | Proskelia | Bone metastasis markers as a target regulating bone metastasis and bone development |
| WO2006091776A2 (en) * | 2005-02-25 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP2479286B1 (en) * | 2006-01-05 | 2013-11-13 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
| CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| WO2009070767A2 (en) | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
| US20110009469A1 (en) * | 2007-12-05 | 2011-01-13 | The Johns Hopkins University | Compositions and methods of treating neoplasia |
| WO2011047147A1 (en) * | 2009-10-14 | 2011-04-21 | Baylor College Of Medicine | Microrna mirna-31 as a therapeutic approach for the treatment of cancer |
| WO2012024612A1 (en) * | 2010-08-20 | 2012-02-23 | Pangea Biosciences, Inc. | Cancer diagnostic and cancer therapeutic |
-
2009
- 2009-12-07 EP EP09831269.7A patent/EP2370091B1/en not_active Not-in-force
- 2009-12-07 WO PCT/US2009/067015 patent/WO2010065961A2/en not_active Ceased
- 2009-12-07 JP JP2011539777A patent/JP2012511031A/ja active Pending
- 2009-12-07 US US13/132,917 patent/US20120041048A1/en not_active Abandoned
- 2009-12-07 CA CA2745919A patent/CA2745919A1/en not_active Abandoned
- 2009-12-07 AU AU2009322137A patent/AU2009322137B2/en not_active Ceased
-
2014
- 2014-01-08 US US14/150,518 patent/US20140343121A1/en not_active Abandoned
- 2014-08-20 JP JP2014167336A patent/JP6110346B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014221834A5 (cg-RX-API-DMAC7.html) | ||
| KR102565758B1 (ko) | 암 예후 예측방법 및 이의 조성물 | |
| Guo et al. | Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer | |
| Ahmetova-c et al. | Genes and athletic performance: an update | |
| Ho et al. | Deregulation of Rab and Rab effector genes in bladder cancer | |
| Petrelli et al. | MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC) | |
| Qian et al. | RNA-Seq technology and its application in fish transcriptomics | |
| US10041126B2 (en) | Monocyte biomarkers for cancer detection | |
| Yang et al. | LncRNA SNHG12 regulated the proliferation of gastric carcinoma cell BGC-823 by targeting microRNA-199a/b-5p. | |
| JP2014532428A5 (cg-RX-API-DMAC7.html) | ||
| US20190127805A1 (en) | Gene signatures for cancer detection and treatment | |
| Liu et al. | Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma | |
| CN113228190A (zh) | 基于预测的肿瘤突变负荷的肿瘤分类 | |
| Wright et al. | Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM) | |
| US20190249257A1 (en) | Long intergenic non-coding rna as pancancer biomarker | |
| Wang et al. | A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival | |
| TW201309805A (zh) | 預測大腸直腸癌復發的生物標記 | |
| Long et al. | Polymorphisms in the precursor microRNAs and aflatoxin B1‐related hepatocellular carcinoma | |
| Biasoli et al. | A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers | |
| Wu et al. | Association on polymorphisms in LncRNA HOTAIR and susceptibility to HNSCC in Chinese population | |
| AU2020215312A1 (en) | Method of predicting survival rates for cancer patients | |
| Thomas et al. | The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth | |
| CA3141356A1 (en) | Pan-cancer transcriptional signature | |
| CA2939924A1 (en) | Method and composition for diagnosis of aggressive prostate cancer | |
| Song et al. | The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma |